Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
出版年份 2018 全文链接
标题
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
作者
关键词
-
出版物
Nature Communications
Volume 9, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-10-11
DOI
10.1038/s41467-018-06653-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- Maintenance of PD-1 on brain-resident memory CD8 T cells is antigen independent
- (2017) Shwetank et al. IMMUNOLOGY AND CELL BIOLOGY
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion
- (2016) Eunseon Ahn et al. JOURNAL OF VIROLOGY
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- (2015) Leisha A. Emens et al. CANCER RESEARCH
- T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate
- (2015) Laura K. Mackay et al. IMMUNITY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells
- (2015) Pamela M. Odorizzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
- (2015) Frauke M. Schnorfeil et al. Journal of Hematology & Oncology
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection
- (2014) Marcus Buggert et al. PLoS Pathogens
- Re-Evaluation of PD-1 Expression by T Cells as a Marker for Immune Exhaustion during SIV Infection
- (2013) Jung Joo Hong et al. PLoS One
- Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral Infection
- (2012) J. M. Angelosanto et al. JOURNAL OF VIROLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating Cellular Polyfunctionality with a Novel Polyfunctionality Index
- (2012) Martin Larsen et al. PLoS One
- Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection
- (2012) M. A. Paley et al. SCIENCE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- SPICE: Exploration and analysis of post-cytometric complex multivariate datasets
- (2011) Mario Roederer et al. CYTOMETRY PART A
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection
- (2011) Charlly Kao et al. NATURE IMMUNOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche
- (2010) A. Banerjee et al. JOURNAL OF IMMUNOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Expression and IL-2 Loss of Cytomegalovirus- Specific T Cells Correlates with Viremia and Reversible Functional Anergy
- (2008) U. Sester et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
- (2008) R. Brad Jones et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started